Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Intas Pharmaceuticals Ltd. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 3 distinct examiners and 3 distinct art units, so the listed work does not center on a shared examiner or examination unit.
ROSSI, JULIA ANNE LORRAIN is the busiest examiner, with 1 pending matter. A matter-specific prosecution strategy is indicated, while common technical positions should be checked for consistency across the separate examination assignments.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROSSI, JULIA ANNE LORRAIN | 1 | 45.7% | +61.3% |
| LIU, TRACY | 1 | 54.5% | +26.9% |
| ABDALHAMEED, MANAHIL MIRGHANI ALI | 1 | 50.3% | +39.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18854146 | AN ORODISPERSIBLE TABLET OF RIVAROXABAN | ROSSI, JULIA ANNE LORRAIN | — |
| 17631676 | PHARMACEUTICAL COMPOSITION COMPRISING HMG-COA REDUCTASE INHIBITORS AND FENOFIBRATE | LIU, TRACY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18854146 | AN ORODISPERSIBLE TABLET OF RIVAROXABAN | ROSSI, JULIA ANNE LORRAIN | — |
| 17631676 | PHARMACEUTICAL COMPOSITION COMPRISING HMG-COA REDUCTASE INHIBITORS AND FENOFIBRATE | LIU, TRACY | — |
| 17627014 | PHARMACEUTICAL COMPOSITION OF IMATINIB | ABDALHAMEED, MANAHIL MIRGHANI ALI | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 1614 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18854146 | AN ORODISPERSIBLE TABLET OF RIVAROXABAN | ROSSI, JULIA ANNE LORRAIN | 1615 | §103§112 | Non-Final OA | — | Pending | Oct 04, 2024 |
| 17631676 | PHARMACEUTICAL COMPOSITION COMPRISING HMG-COA REDUCTASE INHIBITORS AND FENOFIBRATE | LIU, TRACY | 1614 | §103§112 | Non-Final OA | — | Pending | Jan 31, 2022 |
| 17627014 | PHARMACEUTICAL COMPOSITION OF IMATINIB | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | §103 | Non-Final OA | — | Pending | Jan 13, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIntas Pharmaceuticals Ltd. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Julia Anne Lorrain Rossi has the most, with 1 of Intas Pharmaceuticals Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
